Danis, RamazanAkbulut, SamiOzmen, SehmusArikan, Senay2024-04-242024-04-2420101687-96271687-9635https://doi.org/10.1155/2010/537818https://hdl.handle.net/11468/17852Fenofibrate, a fibric acid derivative, is used to treat diabetic dyslipidemia, hypertriglyceridemia, and combined hyperlipidemia, administered alone or in combination with statins. Rhabdomyolysis is defined as a pathological condition involving skeletalmuscle cell damage leading to the release of toxic intracellular material into circulation. Its major causes include muscle compression or overexertion; trauma; ischemia; toxins; cocaine, alcohol, and drug use; metabolic disorders; infections. However, rhabdomyolysis associated with fenofibrate is extremely rare. Herein we report a 45-year-old female patient who was referred to our department because of generalizedmuscle pain, fatigue, weakness, and oliguria over the preceding 3 weeks. On the basis of the pathogenesis and clinical and laboratory examinations, a diagnosis of acute renal failure secondary to fenofibrate-induced rhabdomyolysis wasmade. Weekly followups for patients who are administered fenofibrate are the most important way to prevent possible complications.eninfo:eu-repo/semantics/openAccess[No Keyword]Review Article2010WOS:0002152180001312-s2.0-848598050952081148510.1155/2010/537818Q2N/A